Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

President Trump sent letters Thursday to 17 of the world’s largest drug companies, telling them to take more steps to slash ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...

GlaxoSmithKline Pharmaceuticals Q1 net profit rises 12% to Rs 279 crore, despite slight dip in total income. Company highlights upcoming oncology drug launches.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

By the end of 2024, Axmed had partnered with over 20 organizations across 15 countries. It processed more than 4,200 orders, ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.